Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 3/2019

01-04-2019

Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update

Authors: A. Franco-Moreno, L. Cabezón-Gutiérrez, M. Palka-Kotlowsa, M. Villamayor-Delgado, M. García-Navarro

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2019

Login to get access

Abstract

Cancer is associated with an increased risk of venous thromboembolism of four to sixfold. Cancer-related interventions such as chemotherapy, hormonal therapy and indwelling central venous catheters also increase the risk of venous thromboembolism. Low molecular weight heparin for at least 3–6 months is the current standard of care for the treatment of cancer associated venous thromboembolism. Anticoagulation should be continued as long as the cancer is active. Over the past few years, direct oral anticoagulants have emerged, including one direct thrombin inhibitor (dabigatran etexilate) and three factor Xa inhibitors (apixaban, edoxaban and rivaroxaban). In the randomized controlled trials comparing direct oral anticoagulants with vitamin K antagonists, the direct oral anticoagulants all provide non-inferior in prevention of thromboembolic events in patients with atrial fibrillation, for the prevention and treatment of venous thromboembolism and in acute coronary syndrome. In people with cancer, these drugs have emerged as attractive alternatives for the treatment of venous thromboembolism with the potential to overcome the limitations of low molecular weight heparin. Randomized controlled studies comparing direct oral anticoagulants to low molecular weight heparin in cancer patients are still limited and direct oral anticoagulants are not recommended for the treatment of cancer associated venous thromboembolism yet. However, new emerging data are supporting the use of direct oral anticoagulants in cancer-associated thrombosis. Here, we review recent data on the evidence related to the efficacy and safety of direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer.
Literature
2.
go back to reference Al-Samkari H, Connors JM (2018) The role of direct oral anticoagulants in treatment of cancer-associated thrombosis. Cancers (Basel) 10(8):271CrossRef Al-Samkari H, Connors JM (2018) The role of direct oral anticoagulants in treatment of cancer-associated thrombosis. Cancers (Basel) 10(8):271CrossRef
3.
go back to reference Imberti D, Cimminiello C, Di Nisio M et al (2018) Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance. Expert Opin Pharmacother 19(11):1177–1185CrossRefPubMed Imberti D, Cimminiello C, Di Nisio M et al (2018) Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance. Expert Opin Pharmacother 19(11):1177–1185CrossRefPubMed
4.
go back to reference Voigtlaender M, Langer F (2018) Management of cancer-associated venous thromboembolism—a case-based practical approach. Vasa 47(2):77–89CrossRefPubMed Voigtlaender M, Langer F (2018) Management of cancer-associated venous thromboembolism—a case-based practical approach. Vasa 47(2):77–89CrossRefPubMed
5.
go back to reference Mukai M, Oka T (2018) Mechanism and management of cancer-associated thrombosis. J Cardiol 72(2):89–93CrossRefPubMed Mukai M, Oka T (2018) Mechanism and management of cancer-associated thrombosis. J Cardiol 72(2):89–93CrossRefPubMed
6.
go back to reference Lyman GH, Bohlke K, Khorana AA et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol 33(6):654–656CrossRefPubMedPubMedCentral Lyman GH, Bohlke K, Khorana AA et al (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol 33(6):654–656CrossRefPubMedPubMedCentral
7.
go back to reference Muñoz Martín AJ, Font Puig C, Navarro Martín LM et al (2014) Spanish society for medical oncology. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol 16(12):1079–1090CrossRefPubMedPubMedCentral Muñoz Martín AJ, Font Puig C, Navarro Martín LM et al (2014) Spanish society for medical oncology. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol 16(12):1079–1090CrossRefPubMedPubMedCentral
8.
go back to reference Farge D, Bounameaux H, Brenner B et al (2016) International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 17(10):e452–e466CrossRefPubMed Farge D, Bounameaux H, Brenner B et al (2016) International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 17(10):e452–e466CrossRefPubMed
10.
go back to reference Guyatt GH, Akl EA, Crowther M et al (2012) American College of Chest Physicians. Introduction to the ninth edition: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(Suppl):48S–52SCrossRefPubMedPubMedCentral Guyatt GH, Akl EA, Crowther M et al (2012) American College of Chest Physicians. Introduction to the ninth edition: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(Suppl):48S–52SCrossRefPubMedPubMedCentral
11.
go back to reference Mandala M, Falanga A, Roila F. ESMO Guidelines Working Group (2011) Management of venous thromboembolism (VTE) in cancer patients. Ann Oncol 22(Suppl 6):vi85–vi92PubMed Mandala M, Falanga A, Roila F. ESMO Guidelines Working Group (2011) Management of venous thromboembolism (VTE) in cancer patients. Ann Oncol 22(Suppl 6):vi85–vi92PubMed
12.
go back to reference Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:1729–1735CrossRefPubMed Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162:1729–1735CrossRefPubMed
13.
go back to reference Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153CrossRefPubMed Lee AY, Levine MN, Baker RI et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146–153CrossRefPubMed
14.
go back to reference Hull RD, Pineo GF, Brant RF et al (2006) LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119:1062–1072CrossRefPubMed Hull RD, Pineo GF, Brant RF et al (2006) LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119:1062–1072CrossRefPubMed
15.
go back to reference Deitcher SR, Kessler CM, Merli G et al (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12:389–396CrossRefPubMed Deitcher SR, Kessler CM, Merli G et al (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12:389–396CrossRefPubMed
16.
go back to reference Lee AYY, Kamphuisen PW, Meyer G et al (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314:677–686CrossRefPubMed Lee AYY, Kamphuisen PW, Meyer G et al (2015) Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314:677–686CrossRefPubMed
17.
go back to reference López–Beret P, Orgaz A, Fontcuberta J et al (2001) Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 33:77–90CrossRefPubMed López–Beret P, Orgaz A, Fontcuberta J et al (2001) Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 33:77–90CrossRefPubMed
18.
go back to reference Romera A, Cairols MA, Vila-Coll R et al (2009) A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 37:349–356CrossRefPubMed Romera A, Cairols MA, Vila-Coll R et al (2009) A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 37:349–356CrossRefPubMed
19.
go back to reference Schulman S, Goldhaber SZ, Kearon C et al (2015) Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 114(1):150–157PubMed Schulman S, Goldhaber SZ, Kearon C et al (2015) Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 114(1):150–157PubMed
20.
go back to reference Prins MH, Lensing AW, Brighton TA et al (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of treatment of symptomaticvenous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37–e46CrossRefPubMed Prins MH, Lensing AW, Brighton TA et al (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of treatment of symptomaticvenous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37–e46CrossRefPubMed
21.
go back to reference Agnelli G, Buller HR, Cohen A et al (2015) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 13(12):2187–2191CrossRefPubMed Agnelli G, Buller HR, Cohen A et al (2015) Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 13(12):2187–2191CrossRefPubMed
22.
go back to reference Posch F, Königsbrügge O, Zielinski C et al (2015) Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 136(3):582–589CrossRefPubMed Posch F, Königsbrügge O, Zielinski C et al (2015) Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 136(3):582–589CrossRefPubMed
23.
go back to reference Raskob G, Büller H, Prins M et al (2013) Hokusai-VTE Investigators. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. J Thromb Haemost 11(7):1287–1294CrossRefPubMed Raskob G, Büller H, Prins M et al (2013) Hokusai-VTE Investigators. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study-methodological implications for clinical trials. J Thromb Haemost 11(7):1287–1294CrossRefPubMed
24.
go back to reference Raskob GE, van Es N, Verhamme P et al (2018) Hokusai VTE cancer investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624CrossRefPubMed Raskob GE, van Es N, Verhamme P et al (2018) Hokusai VTE cancer investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624CrossRefPubMed
25.
go back to reference Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (select-d). J Clin Oncol 36(20):2017–2023CrossRefPubMed Young AM, Marshall A, Thirlwall J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (select-d). J Clin Oncol 36(20):2017–2023CrossRefPubMed
27.
go back to reference Mantha S, Laube E, Miao Y, Sarasohn DM et al (2017) Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 43(2):166–171CrossRefPubMed Mantha S, Laube E, Miao Y, Sarasohn DM et al (2017) Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 43(2):166–171CrossRefPubMed
28.
go back to reference Cohen AT, Maraveyas A, Beyer-Westendorf J et al. COSIMO Investigators. COSIMO—patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. Thromb J 16:21 Cohen AT, Maraveyas A, Beyer-Westendorf J et al. COSIMO Investigators. COSIMO—patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. Thromb J 16:21
29.
go back to reference Agnelli G, Becattini C, Bauersachs R et al (2018) Caravaggio study investigators. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thromb Haemost 118(9):1668–1678CrossRefPubMed Agnelli G, Becattini C, Bauersachs R et al (2018) Caravaggio study investigators. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study. Thromb Haemost 118(9):1668–1678CrossRefPubMed
30.
go back to reference Streiff MB, Milentijevic D, McCrae K et al (2018) Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol 93:664–671CrossRefPubMedPubMedCentral Streiff MB, Milentijevic D, McCrae K et al (2018) Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol 93:664–671CrossRefPubMedPubMedCentral
31.
go back to reference Theberge I, Bowdridge J, Forgie MA et al (2017) Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. Thromb Res 152:4–6CrossRefPubMed Theberge I, Bowdridge J, Forgie MA et al (2017) Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. Thromb Res 152:4–6CrossRefPubMed
32.
go back to reference Seo SR, Ryu M-H K, Y-K K, K-P et al (2016) Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer. Ann Oncol 27:695PCrossRef Seo SR, Ryu M-H K, Y-K K, K-P et al (2016) Oral rivaroxaban versus subcutaneous low molecular weight heparin treatment for venous thromboembolism in patients with upper gastrointestinal, hepatobiliary and pancreatic cancer. Ann Oncol 27:695PCrossRef
33.
go back to reference Ross JA, Miller MM, Rojas Hernandez CM (2017) Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res 150:86–89CrossRefPubMed Ross JA, Miller MM, Rojas Hernandez CM (2017) Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: a retrospective analysis. Thromb Res 150:86–89CrossRefPubMed
34.
go back to reference Turpie AGG, Mantovani LG, Haas S et al (2017) Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. Thromb Res 155:23–27CrossRefPubMed Turpie AGG, Mantovani LG, Haas S et al (2017) Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. Thromb Res 155:23–27CrossRefPubMed
36.
go back to reference Sobieraj DM, Baker WL, Smith E et al (2018) Anticoagulation for the treatment of cancer-associated thrombosis: a systematic review and network meta-analysis of randomized trials. Clin Appl Thromb Hemost 24:1076029618800792CrossRef Sobieraj DM, Baker WL, Smith E et al (2018) Anticoagulation for the treatment of cancer-associated thrombosis: a systematic review and network meta-analysis of randomized trials. Clin Appl Thromb Hemost 24:1076029618800792CrossRef
37.
go back to reference Khorana AA, Noble S, Lee AYY et al (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891–1894CrossRefPubMed Khorana AA, Noble S, Lee AYY et al (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891–1894CrossRefPubMed
Metadata
Title
Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update
Authors
A. Franco-Moreno
L. Cabezón-Gutiérrez
M. Palka-Kotlowsa
M. Villamayor-Delgado
M. García-Navarro
Publication date
01-04-2019
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2019
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-018-1783-2

Other articles of this Issue 3/2019

Journal of Thrombosis and Thrombolysis 3/2019 Go to the issue